

REMARKS


The foregoing Preliminary Amendment is requested in order to delete the multiple dependent claims and avoid paying the multiple dependent claims fee.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

Early action on the merits is respectfully requested.

Respectfully submitted,

JACOBSON HOLMAN PLLC

By 
William E. Player
Reg. No. 31,409

400 Seventh Street, N.W.
Washington, D.C. 20004-2201
(202) 638-6666

Atty. Docket: P67083US0
Date: September 4, 2001
WEP:jrc

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS

3. (amended) The use according to claim 1 ~~or 2~~, characterized in that said nucleic acid has the sequence shown in Figure 1, especially that of Seq. Id. No. 1.
4. (amended) The use according to claim 1 ~~claims 1 to 3~~, wherein said nucleic acid codes for an N-terminal fragment of a protein having the sequence MQKILLITFLLGIALAQ.
5. (amended) Use of a nucleic acid according to claim 1 ~~any of claims 1 to 4~~ in a method in which said nucleic acid is combined with the usual, in homologous or heterologous expression, enhancers, promoters, operators, origins, terminators, antibiotic resistances, or other nucleic acids or DNA fragments, or sequences of any kind from viroids, viruses, bacteria, archezoans, protozoans, fungi, plants, animals or humans.
9. (amended) Use of the peptide according to claim 7 ~~or of the nucleic acid according to claim 8~~ for the homologous or heterologous expression of recombinant proteins and peptides, and for homologous or heterologous recombination ("knock-out, "gene replacement").